Sten Verland
Angel Investor @ Forbion Capital Partners
Copenhagen, Denmark
Sten Verland is a partner in the Life Science group and one of the three co-founders. Sten focuses on therapeutics investments.During his career, Sten has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. While at Sunstone, Sten has played a key role in executingtwo exits (Action Pharma and Zymenex). Both deals made it to the global Top Ten list of published upfront cash deals in 2007-2012. Sten holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen. Sten serves as a board member of the Danish Venture Capital Association. In his spare time, Sten is both a keen yachtsman and a big admirer of classical music.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Sten Verland invests in
Stages Sten Verland invests in
Countries Sten Verland invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 2 (100%)
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Health Care 1 (50%)
- Developer Platform 1 (50%)
Stage
- Series A 1 (50%)
- Funding Round 1 (50%)
Country
- Germany 1 (50%)
- Switzerland 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rigontec
|
Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options. | $5.3M / Series A / Mar 24, 2015 | |
| Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinicaltrials in 2011. | $8.5M / Jan 12, 2011 |
Co-Investors
About Forbion Capital Partners
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successfulinvestments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Forbion Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joy Faucher
General Partner
|
|||
Marco Boorsma
General Partner
|
|||
Nanna Lüneborg
General Partner
|
|||
Onno Stolpe
Venture Partner
|
|||
Sander Slootweg
Managing Partner and co-founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sten Verland invest in?
Sten Verland invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sten Verland?
Public channels for Sten Verland include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sten Verland last invest?
The most recent investment recorded for Sten Verland closed in Mar 2015. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
